StockData
Quest Diagnostics Inc logo

Quest Diagnostics Inc (DGX) company profile

DGXNYSEServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 12/308% above fair value
$256.35−5.86 (-2.23%)

Close on Nov 17, 2026Market cap $28.20BP/E 25.6Yield –

About Quest Diagnostics

Services-Medical Laboratories, SIC 8071

Quest Diagnostics provides diagnostic information services and clinical testing solutions derived from routine, non-routine, and specialized laboratory tests. Its operations comprise two primary segments: Diagnostic Information Services, which delivers clinical lab testing, esoteric diagnostics, and diagnostic insights, and Diagnostic Solutions, which includes risk assessment for insurers and healthcare information technology offerings. The company serves physicians across numerous medical specialties, hospitals and health systems, accountable care organizations, health plans, employers, government agencies, pharmaceutical firms, and individual consumers seeking direct testing options.

Headquartered in Secaucus, New Jersey, Quest Diagnostics operates extensively across the United States alongside selective international facilities. Its domestic physical network includes approximately 2,400 patient service centers, around 8,000 total patient access points, laboratories, and specialized logistics assets featuring approximately 5,000 courier vehicles and 18 aircraft. In addition to broad U.S. coverage reaching approximately half of domestic physicians and hospitals annually, the company delivers reference testing to laboratory providers worldwide.

Summary of the business section of Quest Diagnostics's latest annual report, written by StockData.

Company profile

Company

Legal name
Quest Diagnostics Inc
Founded
1967
Headquarters
Secaucus, NJ
Address
500 Plaza Drive 07094
Phone
(973) 520-2700
Employees
57,000, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Florham Park, New Jersey

Stock & identifiers

Ticker
DGX
Exchange
NYSE
IPO date
Dec 13, 1996
Shares outstanding
110M, Oct 15, 2026
Public float
$20.00B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Jun 21, 2005; 2-for-1, Jun 1, 2001
SEC CIK
1022079
CUSIP
74834L100
ISIN
US74834L1008
FIGI
BBG000BN84F3
Share class FIGI
BBG001S9GX43
LEI
8MCWUBXQ0WE04KMXBX50
EIN
16-1387862

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
J. E. DavisCEO and President, Director122,423
Michael J. DeppeSVP, Corp. Controller & CAO35,916
Patrick PlewmanSVP for Diagnostic Services14,684
Subu RamachandranSVP, Regional Businesses2,832
Mark E. DelaneySVP & Chief Commercial Officer12,975
Catherine T. DohertyExecutive Vice President76,501
Sam SamadExecutive Vice President & CFO33,568
Karthik KuppusamySVP, Clinical Solutions15,674
Michael E. PrevoznikSVP & General Counsel66,014
Gary M. PfeifferDirector29,802
Robert B. CarterDirector3,874
Timothy L. MainDirector27,478
Wright Lassiter IIIDirector10,329
Vicky B. GreggDirector18,449
Timothy C. WentworthDirector1,358
Timothy M. RingDirector31,140
Luis DiazDirector5,196
Tracey DoiDirector7,748
Denise M. MorrisonDirector11,929

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$15.50M$26.51M$3.28M$161$148
FY2024$14.40M$24.28M$3.02M$137$129
FY2023$12.67M$9.44M$2.85M$123$126
FY2022
James EDavis
$11.88M$12.71M$3.39M$136$124
FY2022
Stephen HRucskwski
$15.68M$9.82M$3.39M$136$124
FY2022
Stephen HRusckowski
$15.68M$9.82M$3.39M$136$124

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
James E. Davis
Chairman, Chief Executive Officer and President
$1.25M$8.76M$3.00M$2.21M$279.90K$15.50M+8%
Sam A. Samad
Executive Vice President and Chief Financial Officer
$693.27K$2.19M$749.74K$710.36K$82.81K$4.43M+9%
Catherine T. Doherty
Executive Vice President, Regional Businesses
$643.27K$1.68M$574.88K$615.18K$49.94K$3.56M+8%
Michael E. Prevoznik
Senior Vice President and General Counsel
$550.00K$1.13M$387.34K$438.32K$55.91K$2.56M+6%
Karthik Kuppusamy
Senior Vice President, Clinical Solutions
$568.27K$1.10M$374.89K$475.53K$65.65K$2.58M+13%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we have nearly 57,000 employees globally (including LifeLabs’ approximately 6,800), of whom approximately 46,000 are full-time and the remainder are part-time or on-call.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?